CDEK
← All drugs Report issue

perindopril

Trade name: aceon

Small moleculeapproved

Approved

Dec 30, 1993

Perindoprilat is a metabolite of perindopril. Perindopril is a long-acting angiotensin converting enzyme (ACE) inhibitor and it is used to treat high blood pressure, heart failure or stable coronary artery disease. Perindopril is designed to allow oral administration as perindoprilat is poorly absorbed from the gastrointestinal tract. — NCATS

Clinical trial activity

72 trials · 88 clinical orgs · 9 marketing orgs

Phase 1
13
Phase 2
24
Phase 3
12
Phase 4
31

Earliest trial started Jan 10, 2000 (NCT03921736)

Timeline

1990s

  1. Dec 30, 1993

    Earliest FDA Approval

  2. Dec 30, 1993

    Symplmed Pharmaceuticals LLC — NDA Secondary Org

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

  4. Nov 10, 2009

    Ani Pharmaceuticals — Marketing Organization

  5. Nov 10, 2009

    Aurobindo Pharma — Marketing Organization

  6. Nov 10, 2009

    West-Ward Pharmaceutical — Marketing Organization

  7. Nov 10, 2009

    Hikma — Marketing Organization

2010s

  1. Jan 27, 2010

    Lupin — Marketing Organization

  2. Aug 30, 2010

    Apotex — Marketing Organization

  3. Jan 21, 2015

    Adhera — NDA Secondary Org

Indications

Approved for

Studied for

Mechanism of action

Combination products

Approval history

  • approvedDec 30, 1993

Chemistry & pharmacology

Loading structure…

SMILES

CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O
Mol. weight
340.4146 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warningProdrug

Sources

Also known as

  • (2s,3as,7as)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1h-indole-2-carboxylic acid
  • (2s,3as,7as)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1h-indole-2-carboxylic acid
  • aceon
  • aceon
  • aceon
  • coversyl
  • coversyl
  • erbumine
  • erbumine
  • mcn-a-2833
  • mcn-a-2833
  • mcn-a-2833-109
  • mcn-a-2833-109
  • peridopril
  • perindopril
  • perindopril
  • perindopril
  • perindopril
  • perindopril
  • perindopril
  • perindopril
  • perindopril
  • perindopril
  • perindopril
  • perindopril arginine
  • perindopril arginine
  • perindopril arginine
  • perindopril erbumine
  • perindopril erbumine
  • perindopril erbumine
  • perindopril erbumine
  • perindoprilum
  • perindoprilum
  • perindropil
  • s-9490
  • s-9490
  • s-9490-3
  • s-9490-3
  • xoma 985

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06341101Phase 4Mar 26, 2024Maastricht University, ZonMw: The Netherlands Organisation for Health Research and Development
NCT06213610Phase 1Jan 9, 2024Pharmtechnology LLC
NCT06275763Phase 4Oct 20, 2023Instituto Nacional de Cardiologia de Laranjeiras, Medical University of Warsaw
NCT07259733N/AJul 15, 2023Instituto Dante Pazzanese de Cardiologia, Servier
NCT05940909Phase 1Jun 24, 2023Ligand Research, LLC, Pharmtechnology LLC
NCT05683301Phase 4Aug 30, 2022All India Institute of Medical Sciences, Government of India, Imperial College London
NCT05232370Phase 2Jan 1, 2022Unidad de Investigacion Medica en Enfermedades Renales
NCT04591808Phase 3Sep 9, 2021Servier
NCT05470764Phase 1May 30, 2021Darnitsa Pharmaceutical Company, International Partnership for Microbicides
NCT05464745Phase 1May 19, 2021Darnitsa Pharmaceutical Company, International Partnership for Microbicides
NCT04591210Phase 3Oct 30, 2020University of Ottawa
NCT04342351Phase 4May 1, 2020Jiao Tong University
NCT04306627Phase 4Apr 15, 2020Servier, Yerevan State Medical University, Armenia
NCT05535595Phase 4Nov 6, 2019Yonsei University
NCT04148820Phase 4Nov 1, 2019University of Roma La Sapienza
NCT04106219Phase 1Oct 21, 2019Eli Lilly, National Cancer Institute (NCI)
NCT03898791Phase 1/Phase 2 (Phase 2)Jul 1, 2019Eli Lilly
NCT03955939Phase 1Jun 20, 2019Eli Lilly
NCT05820880Phase 3May 6, 2019Servier
NCT04023565Phase 4Mar 11, 2019Volgograd State Medical University
Showing 20 of 72 trials
Page 1 / 4

Organizations

Research & Development (88)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ServierFor profit11542000
University of YaoundeAcademic/Hospital4412016
Eli LillyFor profit3322019
University of LondonAcademic/Hospital3222000
University of Roma La SapienzaAcademic/Hospital3312016
University of TorontoAcademic/Hospital3322010
Baylor UniversityAcademic/Hospital2212009
Darnitsa Pharmaceutical CompanyFor profit2212021
Haisco PharmaceuticalFor profit2212018
Institut National de la Santé Et de la Recherche Médicale, FranceAcademic/Hospital2122007
International Partnership for MicrobicidesAcademic/Hospital2012021
Medical University of ViennaAcademic/Hospital2112016
Monash UniversityAcademic/Hospital2222004
Pharmtechnology LLCFor profit2212023
Roxane LaboratoriesFor profit2212007
Alice Brenaa FoundationAcademic/Hospital1012009
All India Institute of Medical SciencesAcademic/Hospital1012022
AurKa Pharma Inc.For profit1112017
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'AragonaAcademic/Hospital1112014
BayerFor profit1012016
88 organizations
Page 1 / 5

Marketing (11)

OrganizationOrg typeRelationshipDate
AdheraFor profitNDA2Jan 21, 2015
Ani PharmaceuticalsFor profitMKTGNov 10, 2009
Ani PharmaceuticalsFor profitSYNNov 10, 2009
ApotexFor profitMKTGAug 30, 2010
Aurobindo PharmaFor profitMKTGNov 10, 2009
HikmaFor profitMKTGNov 10, 2009
HikmaFor profitSYNNov 10, 2009
LupinFor profitMKTGJan 27, 2010
Rhone PoulencFor profitNDA—
Symplmed Pharmaceuticals LLCFor profitNDA2Dec 30, 1993
West-Ward PharmaceuticalFor profitMKTGNov 10, 2009